$MRZM
Marizyme Inc Stock $mrzm

$mrzm Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023008 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$76.01K	$61.81K
YoY Change	104.22%	-61.56%
Cost Of Revenue	$15.50K	$11.03K
YoY Change	-15.58%	-92.65%
Gross Profit	$60.51K	$50.78K
YoY Change	220.84%	-40.03%
Gross Profit Margin	79.61%	82.16%
Selling, General & Admin	$1.375M	$3.071M	$2.567M
YoY Change	-22.52%	-27.05%	13.82%
% of Gross Profit	2272.3%	6047.09%
Research & Development	$708.2K	$1.371M	$1.218M
YoY Change	192.96%	460.5%
% of Gross Profit	1170.42%	2700.81%
Depreciation & Amortization	$210.4K	$210.4K	$210.4K
YoY Change			-49.5%
% of Gross Profit	347.65%	414.26%
Operating Expenses	$2.309M	$4.664M	$3.995M
YoY Change	30.11%	124.91%	77.18%
Operating Profit	-$2.233M	-$4.602M	-$3.995M
YoY Change	27.18%	140.58%	80.63%
Interest Expense	-$810.6K	-$530.2K	-$299.5K
YoY Change	1054.37%	12554.65%
% of Operating Profit
Other Income/Expense, Net	$680.4K	-$2.322M	-$1.830M
YoY Change	250.72%	-948.11%
Pretax Income	-$1.553M	-$6.924M	-$6.125M
YoY Change	-4.86%	79.81%	176.91%
Income Tax
% Of Pretax Income
Net Earnings	-$1.553M	-$6.924M	-$6.125M
YoY Change	-4.86%	322.47%	176.91%
Net Earnings / Revenue	-2042.62%	-11202.23%
Basic Earnings Per Share	-$0.04	-$0.17	-$0.15
Diluted Earnings Per Share	-$38.03K	-$169.6K	-$150.8K
COMMON SHARES
Basic Shares Outstanding	40.83M shares	40.83M shares	40.63M shares
Diluted Shares Outstanding	40.83M shares	40.83M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.182M	$2.045M	$3.173M
YoY Change	6992.08%	97280.0%	280.01%
Cash & Equivalents	$1.182M	$2.045M	$3.173M
Short-Term Investments
Other Short-Term Assets	$839.8K	$235.4K	$469.9K
YoY Change	2299.49%	729.97%	644.71%
Inventory	$251.2K	$268.4K	$15.54K
Prepaid Expenses	$839.8K	$235.4K
Receivables	$54.23K	$53.08K	$8.650K
Other Receivables	$14.13K	$12.59K	$20.81K
Total Short-Term Assets	$2.342M	$2.614M	$3.688M
YoY Change	1333.49%	1470.52%	276.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.61K	$12.68K	$1.111M
YoY Change	-98.92%	-98.97%	-11.98%
Goodwill	$7.191M	$7.191M
YoY Change
Intangibles	$52.24M	$52.45M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$369.1K	$369.1K	$369.1K
YoY Change	-0.51%	-0.51%	-0.51%
Total Long-Term Assets	$61.38M	$61.69M	$61.33M
YoY Change	15.09%	15.27%	40.79%
TOTAL ASSETS
Total Short-Term Assets	$2.342M	$2.614M	$3.688M
Total Long-Term Assets	$61.38M	$61.69M	$61.33M
Total Assets	$63.73M	$64.30M	$65.01M
YoY Change	19.11%	19.79%	45.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$848.4K	$617.0K	$822.6K
YoY Change	-39.27%	-48.97%	84.82%
Accrued Expenses	$420.9K	$418.3K	$277.1K
YoY Change	61.82%	72.1%	-8.87%
Deferred Revenue
YoY Change
Short-Term Debt	$213.6K	$241.4K	$284.9K
YoY Change
Long-Term Debt Due	$213.6K	$241.4K
YoY Change
Total Short-Term Liabilities	$1.606M	$1.500M	$1.656M
YoY Change	-30.04%	-12.62%	121.04%
LONG-TERM LIABILITIES
Long-Term Debt	$1.649M	$843.0K	$318.1K
YoY Change	818.76%	24053.3%
Other Long-Term Liabilities	$19.52M	$20.61M	$17.79M
YoY Change	80.98%	92.16%	1718.28%
Total Long-Term Liabilities	$21.17M	$21.45M	$18.10M
YoY Change	93.06%	99.95%	1750.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.606M	$1.500M	$1.656M
Total Long-Term Liabilities	$21.17M	$21.45M	$18.10M
Total Liabilities	$22.78M	$22.95M	$19.76M
YoY Change	71.75%	84.42%	1043.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.43M	-$60.87M
YoY Change
Common Stock	$40.83K	$40.83K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$40.95M	$41.35M	$45.25M
YoY Change
Total Liabilities & Shareholders Equity	$63.73M	$64.30M	$65.01M
YoY Change	19.11%	19.79%	45.97%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.553M	-$6.924M	-$6.125M
YoY Change	-4.86%	322.47%	176.91%
Depreciation, Depletion And Amortization	$210.4K	$210.4K	$210.4K
YoY Change			-49.5%
Cash From Operating Activities	-$2.210M	-$2.742M	-$4.314M
YoY Change	65.27%	201.12%	108.89%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.348M	1.614M	3.414M
YoY Change	-0.32%	2053.36%
NET CHANGE
Cash From Operating Activities	-2.210M	-2.742M	-4.314M
Cash From Investing Activities
Cash From Financing Activities	1.348M	1.614M	3.414M
Net Change In Cash	-862.7K	-1.128M	$0.00
YoY Change	-6025.27%	34.99%
FREE CASH FLOW
Cash From Operating Activities	-$2.210M	-$2.742M	-$4.314M
Capital Expenditures			$0.00
Free Cash Flow			-$4.314M
YoY Change			109.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001413754
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	MRZM	Stockbased Compensation Restricted Common Stock StockbasedCompensationRestrictedCommonStock		usd
	MRZM	Interest And Accretion On Convertible Notes And Notes Payable InterestAndAccretionOnConvertibleNotesAndNotesPayable		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes		usd
	MRZM	Contingent Liabilities Noncash ContingentLiabilitiesNoncash		usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2020Q4	us-gaap	Goodwill Goodwill		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53223
	dei	Entity Registrant Name EntityRegistrantName	MARIZYME, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5464863
	dei	Entity Address Address Line1 EntityAddressAddressLine1	555 Heritage Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33458
	dei	City Area Code CityAreaCode	(925)
	dei	Local Phone Number LocalPhoneNumber	400-3123
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40828188	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2044976	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4072339	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53083	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8650	usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables	12589	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	41307	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	235382	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	257169	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	268413	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	22353	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2614443	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	4401818	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12681	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12817	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1667151	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1158776	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52445606	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52866192	usd
CY2022Q2	MRZM	Prepaid Royalties Noncurrent PrepaidRoyaltiesNoncurrent	339091	usd
CY2021Q4	MRZM	Prepaid Royalties Noncurrent PrepaidRoyaltiesNoncurrent	339091	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	30000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	30000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	7190656	usd
CY2021Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	61685185	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	61597532	usd
CY2022Q2	us-gaap	Assets Assets	64299628	usd
CY2021Q4	us-gaap	Assets Assets	65999350	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	617041	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1596147	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	241392	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	127798	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	223661	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1132634	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	418330	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	277142	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1500424	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3133721	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1248821	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	881634	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	469252	usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	842946	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	26065	usd
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4423725	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2485346	usd
CY2022Q2	MRZM	Contingent Liabilities ContingentLiabilities	14935000	usd
CY2021Q4	MRZM	Contingent Liabilities ContingentLiabilities	11313000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21450492	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15175297	usd
CY2022Q2	us-gaap	Liabilities Liabilities	22950916	usd
CY2021Q4	us-gaap	Liabilities Liabilities	18309018	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528188	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	40828	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	40528	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102180316	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40828188	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40828188	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528188	shares
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95473367	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60872432	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47823563	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41348712	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47690332	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64299628	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65999350	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61809	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	160785	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61809	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	234737	usd
CY2022Q2	MRZM	Direct Costs Of Revenue DirectCostsOfRevenue	11025	usd
CY2021Q2	MRZM	Direct Costs Of Revenue DirectCostsOfRevenue	119221	usd
	MRZM	Direct Costs Of Revenue DirectCostsOfRevenue	11025	usd
	MRZM	Direct Costs Of Revenue DirectCostsOfRevenue	150063	usd
CY2022Q2	MRZM	Professional Fees Related Parties ProfessionalFeesRelatedParties	163200	usd
CY2021Q2	MRZM	Professional Fees Related Parties ProfessionalFeesRelatedParties	90000	usd
	MRZM	Professional Fees Related Parties ProfessionalFeesRelatedParties	266400	usd
	MRZM	Professional Fees Related Parties ProfessionalFeesRelatedParties	180000	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	873865	usd
CY2021Q2	us-gaap	Professional Fees ProfessionalFees	455552	usd
	us-gaap	Professional Fees ProfessionalFees	1417905	usd
	us-gaap	Professional Fees ProfessionalFees	984625	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	902106	usd
CY2021Q2	us-gaap	Salaries And Wages SalariesAndWages	683197	usd
	us-gaap	Salaries And Wages SalariesAndWages	1817746	usd
	us-gaap	Salaries And Wages SalariesAndWages	1567238	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1371470	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	244686	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2589766	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	636190	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	676242	usd
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	194657	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1392674	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	562375	usd
CY2022Q2	MRZM	Depreciation Depletion And Amortization1 DepreciationDepletionAndAmortization1	210361	usd
CY2021Q2	MRZM	Depreciation Depletion And Amortization1 DepreciationDepletionAndAmortization1	26715	usd
	MRZM	Depreciation Depletion And Amortization1 DepreciationDepletionAndAmortization1	420722	usd
	MRZM	Depreciation Depletion And Amortization1 DepreciationDepletionAndAmortization1	-186216	usd
CY2022Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	618498	usd
CY2021Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	349496	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1009070	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	645068	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4663567	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2073524	usd
	us-gaap	Operating Expenses OperatingExpenses	8658908	usd
	us-gaap	Operating Expenses OperatingExpenses	4359343	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4601758	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1912739	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8597099	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4124606	usd
CY2022Q2	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	-530226	usd
CY2021Q2	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	-4189	usd
	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	-829770	usd
	MRZM	Interest And Accretion Expenses Other InterestAndAccretionExpensesOther	-4189	usd
CY2022Q2	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-1792000	usd
CY2021Q2	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	278000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-3622000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	278000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2322226	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	273811	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4451770	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	273811	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923984	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1638928	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13048869	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3850795	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q2	us-gaap	Weighted Average Limited Partnership Units Outstanding WeightedAverageLimitedPartnershipUnitsOutstanding	40828188	shares
CY2021Q2	us-gaap	Weighted Average Limited Partnership Units Outstanding WeightedAverageLimitedPartnershipUnitsOutstanding	35928188	shares
	us-gaap	Weighted Average Limited Partnership Units Outstanding WeightedAverageLimitedPartnershipUnitsOutstanding	40728740	shares
	us-gaap	Weighted Average Limited Partnership Units Outstanding WeightedAverageLimitedPartnershipUnitsOutstanding	35928188	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	45287628	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	334385	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2211867	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	43410146	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	194657	usd
CY2021Q2	MRZM	Adjustment Of Warrants Value In Connection With Finalizing Business Combination AdjustmentOfWarrantsValueInConnectionWithFinalizingBusinessCombination	-732300	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1638928	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	41233575	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	47690332	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	716432	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2969916	usd
CY2022Q1	MRZM	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6124885	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45254795	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	676242	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2341659	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923984	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41348712	usd
	us-gaap	Profit Loss ProfitLoss	-13048869	usd
	us-gaap	Profit Loss ProfitLoss	-3850795	usd
	MRZM	Depreciation Depletion And Amortization1 DepreciationDepletionAndAmortization1	420722	usd
	MRZM	Depreciation Depletion And Amortization1 DepreciationDepletionAndAmortization1	-186216	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1392674	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	529042	usd
	MRZM	Stockbased Compensation Restricted Common Stock StockbasedCompensationRestrictedCommonStock	33333	usd
	MRZM	Interest And Accretion On Convertible Notes And Notes Payable InterestAndAccretionOnConvertibleNotesAndNotesPayable	829770	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1850533	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	-3622000	usd
	MRZM	Gain Loss On Fair Value Of Contingent Liabilities GainLossOnFairValueOfContingentLiabilities	278000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	15715	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	78686	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-21787	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-44701	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	246060	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-39600	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-973544	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	506418	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-908973	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	265000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7055675	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2975603	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5120743	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	74945	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	95431	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5028312	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74945	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2027363	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2900658	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4072339	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2902762	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2044976	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2104	usd
	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	1938379	usd
	MRZM	Derivative Liabilities And Debt Discount Issued In Connection With Convertible Notes DerivativeLiabilitiesAndDebtDiscountIssuedInConnectionWithConvertibleNotes	24982	usd
	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	3461042	usd
	MRZM	Warrants And Debt Discount Issued In Connection With Convertible Notes WarrantsAndDebtDiscountIssuedInConnectionWithConvertibleNotes	49963	usd
	MRZM	Settlement Of Notes Payable With Convertible Notes SettlementOfNotesPayableWithConvertibleNotes	278678	usd
	MRZM	Contingent Liabilities Noncash ContingentLiabilitiesNoncash	9648000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60872432	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47823563	usd
CY2022Q2	MRZM	Working Capital WorkingCapital	1114019	usd
CY2021Q4	MRZM	Working Capital WorkingCapital	1268097	usd
CY2022Q2	us-gaap	Cash Cash	2044976	usd
CY2021Q4	us-gaap	Cash Cash	4072339	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zVHHxgeBPrmf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities and deferred tax valuations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	MRZM	Midrange Average Estimated Interest Rate MidrangeAverageEstimatedInterestRate	0.206	pure
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	293000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	772000	usd
	us-gaap	Royalty Expense RoyaltyExpense	4760000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	3988000	usd
CY2021Q4	MRZM	Liquidation Preference Fair Market Value LiquidationPreferenceFairMarketValue	1823000	usd
CY2021Q2	MRZM	Contingent Liabilities ContingentLiabilities	24982	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	418330	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	277142	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1248821	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	881634	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	209025	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	469252	usd
CY2020Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y6M
CY2020Q4	us-gaap	Area Of Land AreaOfLand	10300
CY2022Q2	us-gaap	Area Of Land AreaOfLand	3053
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P4Y29D
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	110353	usd
	us-gaap	Payments For Rent PaymentsForRent	221253	usd
CY2021Q2	us-gaap	Payments For Rent PaymentsForRent	55812	usd
	us-gaap	Payments For Rent PaymentsForRent	91412	usd
CY2021Q4	us-gaap	Goodwill Goodwill	7190656	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1667151	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1158776	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1667151	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1158776	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	206583	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	423495	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	434082	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	444934	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	266034	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1775128	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	107977	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1667151	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	53492745	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1047139	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	52445606	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	53492745	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-626553	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	52866192	usd
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	7190656	usd
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	42278211	usd
CY2021	us-gaap	Indefinite Lived Intangible Assets Purchase Accounting Adjustments IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustments	4022271	usd
CY2021	MRZM	Indefinite Lived Intangible Assets Purchase Accounting Adjustments One IndefiniteLivedIntangibleAssetsPurchaseAccountingAdjustmentsOne	6600000	usd
CY2021	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	2775	usd
CY2021	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	37065	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	52866192	usd
	MRZM	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	420586	usd
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	52445606	usd
CY2022Q2	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	524884	usd
	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	816881	usd
CY2021Q2	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	4189	usd
	MRZM	Interest And Accretion Expenses InterestAndAccretionExpenses	4189	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	26065	usd
	MRZM	Convertible Notes Issued New Securities ConvertibleNotesIssuedNewSecurities	5815138	usd
	MRZM	Deferred Finance Costs DeferredFinanceCosts	415717	usd
	MRZM	Debt Instrument Unamortized Discounts DebtInstrumentUnamortizedDiscounts	5399421	usd
	MRZM	Debt Accretion Expenses DebtAccretionExpenses	816881	usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	842946	usd
CY2022Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	13271177	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7482104	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-12428231	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-7456039	usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	842946	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	26065	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40828188	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40828188	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528188	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528188	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	300000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1532500	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3800943	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.36
CY2021	MRZM	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P8Y9M25D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1532500	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.51
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1682500	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.36
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3650943	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
	MRZM	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3	P8Y4M2D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1951117	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
	MRZM	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y11M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	196000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4050943	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5505984	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2970111	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M7D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4629586	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5000000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	295750	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19255465	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12144838	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	676242	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1392674	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	194657	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	562375	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2154935	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M6D
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	86400	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	101781	usd
CY2022Q2	us-gaap	Prepaid Royalties PrepaidRoyalties	339091	usd
CY2021Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	339091	usd
	MRZM	Royalties Percentage RoyaltiesPercentage	0.10	pure

Files In Submission

Name	View Source	Status
0001493152-22-023008-index-headers.html	Edgar Link	pending
0001493152-22-023008-index.html	Edgar Link	pending
0001493152-22-023008.txt	Edgar Link	pending
0001493152-22-023008-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
ex10-1_002.jpg	Edgar Link	pending
ex10-1_003.jpg	Edgar Link	pending
ex10-1_004.jpg	Edgar Link	pending
ex10-1_005.jpg	Edgar Link	pending
ex10-1_006.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
ex4-4.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
ex4-5_001.jpg	Edgar Link	pending
ex4-5_002.jpg	Edgar Link	pending
ex4-5_003.jpg	Edgar Link	pending
ex4-5_004.jpg	Edgar Link	pending
ex4-5_005.jpg	Edgar Link	pending
ex4-5_006.jpg	Edgar Link	pending
ex4-5_007.jpg	Edgar Link	pending
ex4-5_008.jpg	Edgar Link	pending
ex4-5_009.jpg	Edgar Link	pending
ex4-5_010.jpg	Edgar Link	pending
ex4-5_011.jpg	Edgar Link	pending
ex4-5_012.jpg	Edgar Link	pending
ex4-5_013.jpg	Edgar Link	pending
ex4-5_014.jpg	Edgar Link	pending
ex4-5_015.jpg	Edgar Link	pending
ex4-5_016.jpg	Edgar Link	pending
ex4-5_017.jpg	Edgar Link	pending
ex4-5_018.jpg	Edgar Link	pending
ex4-5_019.jpg	Edgar Link	pending
ex4-5_020.jpg	Edgar Link	pending
ex4-5_021.jpg	Edgar Link	pending
ex4-5_022.jpg	Edgar Link	pending
ex4-5_023.jpg	Edgar Link	pending
ex4-5_024.jpg	Edgar Link	pending
ex4-5_025.jpg	Edgar Link	pending
ex4-5_026.jpg	Edgar Link	pending
ex4-5_027.jpg	Edgar Link	pending
ex4-5_028.jpg	Edgar Link	pending
ex4-5_029.jpg	Edgar Link	pending
ex4-5_030.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrzm-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
mrzm-20220630_cal.xml	Edgar Link	unprocessable
mrzm-20220630_def.xml	Edgar Link	unprocessable
mrzm-20220630_pre.xml	Edgar Link	unprocessable
mrzm-20220630_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRZM
Marizyme Inc Stock $mrzm

2022 Q3 Form 10-Q Financial Statement

#000149315222023008 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM Marizyme Inc Stock $mrzm

2022 Q3 Form 10-Q Financial Statement

#000149315222023008 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRZM
Marizyme Inc Stock $mrzm